A new method to express siRNA

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$132,320.00
Award Year:
2005
Program:
SBIR
Phase:
Phase I
Contract:
1R43GM074318-01
Award Id:
76341
Agency Tracking Number:
GM074318
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Ambion, Inc. (Currently AMBION DIAGNOSTICS, INC.)
Ambion, Inc., 2130 Woodward Street, Austin, TX, 78744
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
ZHONGTING HU
(512) 651-0200
ZHU@AMBION.COM
Business Contact:
BERNARD ANDRUSS
(512) 651-0200
BANDRUSS@AMBION.COM
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Small interfering RNA (siRNA) specifically degrades target complementary mRNAs in cells. The vector system that controls the expression of siRNAs has been widely used for academic research and clinical therapy. Although Pol III promoters are used to express small hairpin RNA to down-regulate genes in mammalian cells, the efficiency is not as potent as once hoped. It is also difficult to determine if cells express siRNA after transfection and it is hard to identify which cells express siRNAs. In this phase I study, we propose a novel Pol II promoter-controlled siRNA expression system. In this system, individual cells expressing siRNA can be traced and visualized by light microscopy. To detect expressing siRNA in cells more efficiently, we have also designed a new acrylamide-gel based isolation system that can enrich siRNAs (or any small RNA molecules) easily, quickly and with high efficiency. The new Pol ll-controlled siRNA expression vector and small RNA enrichment system has been devised and primarily tested. In this Phase I study, we will finally construct and optimize the siRNA expression vector and enrichment system. In phase II of the project, we will expand this new siRNA expression system to degrade specific mRNAs in a tissue- or cell type-specific manner. The specific aims of this Phase I feasibility study are: 1). Develop new Pol II promoter-controlled siRNA expressing vectors to down-regulate mRNA expressions 2). Develop a new small RNA isolation and enrichment system Successful completion of these goals will provide a novel system allowing researchers the ability to easily and verifiably down-regulate the expression of target genes. Furthermore, it will prove the feasibility of this approach and provide a firm foundation for the Phase II development of regulated knockdown strategies that will greatly enhance gene function studies.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government